Professor Cass Byrnes discusses the treatment of cystic fibrosis patients with a CFTR modulator, and the evidence for the use of Trikafta

Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is funded for people aged 6 years and above with cystic fibrosis (CF), subject to eligibility criteria.

Professor Cass Byrnes MBChB, FRACP, MD (Auckland), GCCE (New South Wales) is in the Paediatric Department of the University of Auckland and a Paediatric Respiratory Specialist at Starship Children's Health and Kidz First Hospital.

GORD – How to Optimise Management

Presented by Gastroenterologist Alasdair Patrick

Professor Cass Byrnes discusses the treatment of cystic fibrosis patients with a CFTR modulator, and the evidence for the use of Trikafta

GORD – How to Optimise Management

Get Free publications straight to your inbox.